Neflamapimod (VX-745) Clinical Trials

Size	Price	Qty
10mg	USD 480

Clinical Trials

Neflamapimod (VX-745), a targeted p38 MAP kinase inhibitor, has been evaluated in several Phase 2 clinical trials assessing its therapeutic potential, safety, and biomarker impact in central nervous system inflammatory disorders. Sponsored by EIP Pharma Inc. alongside academic institutions such as University Hospital, Toulouse, these studies target neurodegenerative and cerebrovascular conditions, including Alzheimer's disease, dementia with Lewy bodies, Huntington disease, ischemic stroke, and nonfluent variant primary progressive aphasia. Trial recruitment statuses across these protocols range from completed and active non-recruiting to terminated investigations.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06987643	ACTIVE_NOT_RECRUITING	Moderate to Severe Acute Ischaemic Stroke; Ischaemic Stroke	EIP Pharma Inc	2025-06-20	PHASE2
NCT07033481	ACTIVE_NOT_RECRUITING	Nonfluent Variant Primary Progressive Aphasia (nfvPPA)	EIP Pharma Inc	2025-10-02	PHASE2
NCT06815965	COMPLETED	Dementia With Lewy Bodies (DLB)	EIP Pharma Inc	2024-10-16	PHASE2
NCT05869669	COMPLETED	Dementia With Lewy Bodies	EIP Pharma Inc	2023-05-01	PHASE2
NCT03435861	COMPLETED	Alzheimer Disease	University Hospital, Toulouse	2018-10-08	PHASE2
NCT03980938	TERMINATED	Huntington Disease	EIP Pharma Inc	2019-07-08	PHASE2
NCT04001517	COMPLETED	Dementia With Lewy Bodies (DLB)	EIP Pharma Inc	2019-09-30	PHASE2
NCT03402659	COMPLETED	Alzheimer Disease	EIP Pharma Inc	2017-12-29	PHASE2
NCT02423200	COMPLETED	Alzheimer's Disease	EIP Pharma Inc	2015-04	PHASE2
NCT02423122	COMPLETED	Alzheimer's Disease; Mild Cognitive Impairment	EIP Pharma Inc	2015-04	PHASE2
NCT02423200	Completed	Alzheimer''s Disease	EIP Pharma Inc	2015-04	Phase 2

(data from https://clinicaltrials.gov, updated on 2026-07-08)

Check the Neflamapimod (VX-745) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Neflamapimod (VX-745) selectively binds to p38α mitogen-activated protein kinase (MAPK) to inhibit its catalytic activity, thereby preventing the phosphorylation and downstream production of pro-inflammatory cytokines such as interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha. By reducing neuroinflammation and cytokine-mediated microglial activation, this p38α-targeted pathway blockade aims to alleviate neurodegenerative pathology and cognitive impairment in clinical trial conditions such as Alzheimer's disease and dementia with Lewy bodies.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).